Detecting damaged peptides without separating them: the wager of ion mobility
AI-generated hypothesis · Pre-publication · To be tested experimentally
Table of contents — full brief
- Hypothesis and mechanismCausal chain, key assumptions, residual unknowns
- State of the artVerified references and counter-evidence (DOIs)
- Falsifiable predictionsQuantitative bounds, statistical tests, H0
- Experimental protocolThree phases — in silico → minimal → full
- Impact analysisNovelty, residual gaps, available data
- Panel reviewFive personas + meta-review
Verified references
5 of 17 references- DOI: 10.1039/c7cc03321d ↗
Distinguishing D- and L-Aspartic and Isoaspartic Acids in Amyloid β Peptides with Ultrahigh Resolution Ion Mobility Spectrometry
2017 - DOI: 10.1021/acs.analchem.1c00445 ↗
Analysis of Peptide Stereochemistry in Single Cells by Capillary Electrophoresis—Trapped Ion Mobility Spectrometry Mass Spectrometry
2021 - DOI: 10.1021/acs.analchem.3c00551 ↗
Coupling High-Field Asymmetric Waveform Ion Mobility Spectrometry with Capillary Zone Electrophoresis-Tandem Mass Spectrometry for Top-Down Proteomics
2023 - DOI: 10.1021/acs.jproteome.2c00337 ↗
Coupling High-Field Asymmetric Ion Mobility Spectrometry with Capillary Electrophoresis-Electrospray Ionization-Tandem Mass Spectrometry Improves Protein Identifications in Bottom-Up Proteomic Analysis of Low Nanogram Samples
2022 - DOI: 10.1021/acs.analchem.3c02120 ↗
Full Separation and Sequencing of Isomeric Proteoforms in the Middle-Down Mass Range Using Cyclic Ion Mobility and Electron Capture Dissociation.
2023
+ 12 more references
Detailed panel scores
The protocol is structured into three phases with explicit GO/NO-GO criteria and pivot plans, which demonstrates rigorous planning and a willingness to adapt to interim results.
The hypothesis rests on a well-established chemical mechanism (succinimide-mediated deamidation/isomerisation), correctly described and duly anchored in the classical literature (Bornstein, 1988; Mamula, 1996). The causal chain from Asn deamidation to isoAsp formation and subsequently to CCS perturbation is chemically sound and internally coherent.
The hypothesis is mechanistically grounded: the succinimide pathway for Asn deamidation is well established, and the resulting isoAsp backbone kink is a plausible source of CCS perturbation. The causal chain from chemistry to IMS readout is logically coherent.
The market for synthetic peptides (GLP-1, hormones, therapeutic peptides) exceeds $50 billion and is growing by 10–15% per year. Problems of deamidation/isomerisation (isoAsp) are a major cause of batch rejection and recalls. A label-free assay, without chromatography, rapid (a few minutes versus 30–60 min by LC-MS/MS) and quantitative, addresses a genuine need of CDMOs (Lonza, Bachem, PolyPeptide) and of Big Pharma QC laboratories.
Strong alignment with the Horizon Europe 2025-2026 calls on advanced analytical methods for the characterisation of biotherapeutics (Cluster 1, destination 'Health', call HORIZON-HLTH-2026-TOOL-08: 'Advanced analytical tools for biopharmaceutical quality control'). The project addresses directly the regulatory need for label-free methods to detect deamidation, a critical quality attribute (CQA) of mAbs and synthetic peptides.
Receive the next SPORE hypotheses
Once or twice a month, in your inbox. No spam, one-click unsubscribe.
Your data stays private. No third-party sharing. GDPR-compliant.